Network Matters

News and Information for the Harvard Pilgrim Health Care Network

July 2014

P&T Committee Updates 

At a March 3, 2014 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed several medications and decided the following.

P&T Committee Review and Decisions
Name	Indication	Decision
Duavee (conjugated estrogens + bazedoxifene)	Duavee is used to prevent osteoporosis and treat moderate to severe vasomotor symptoms of menopause in postmenopausal women (with a uterus).	Continued coverage at • Tier 3 for 3-Tier formulary • Tier 4 for 4-Tier formulary • Tier 3 for Medicare Part D
Farxiga (dapagliflozin)	Farxiga and Invokana are used in addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes.	Continued coverage at • Tier 3 for 3-Tier formulary • Tier 4 for 4-Tier formulary • Tier 4 for Medicare Part D
Invokana (canagliflozin)		Continued coverage at • Tier 3 for 3-Tier formulary • Tier 4 for 4-Tier formulary • Tier 4 for Medicare Part D

Email this article to a colleague